<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29909021</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>09</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>155</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12.</ArticleTitle>
        <Pagination>
          <StartPage>880</StartPage>
          <EndPage>891.e8</EndPage>
          <MedlinePgn>880-891.e8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2018.05.051</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(18)34656-0</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS">Immunotherapies are ineffective against pancreatic cancer. We investigated whether the activity of nuclear factor (NF)κB in pancreatic stromal cells contributes to an environment that suppresses antitumor immune response.</AbstractText>
          <AbstractText Label="METHODS">Pancreata of C57BL/6 or Rag1<sup>-/-</sup> mice were given pancreatic injections of a combination of Kras<sup>G12D/+</sup>; Trp53 <sup>R172H/+</sup>; Pdx-1cre (KPC) pancreatic cancer cells and pancreatic stellate cells (PSCs) extracted from C57BL/6 (control) or mice with disruption of the gene encoding the NFκB p50 subunit (Nfkb1 or p50<sup>-/-</sup> mice). Tumor growth was measured as an endpoint. Other mice were given injections of Lewis lung carcinoma (LLC) lung cancer cells or B16-F10 melanoma cells with control or p50<sup>-/-</sup> fibroblasts. Cytotoxic T cells were depleted from C57BL/6 mice by administration of antibodies against CD8 (anti-CD8), and growth of tumors from KPC cells, with or without control or p50<sup>-/-</sup> PSCs, was measured. Some mice were given an inhibitor of CXCL12 (AMD3100) and tumor growth was measured. T-cell migration toward cancer cells was measured using the Boyden chamber assay.</AbstractText>
          <AbstractText Label="RESULTS">C57BL/6 mice coinjected with KPC cells (or LLC or B16-F10 cells) and p50<sup>-/-</sup> PSCs developed smaller tumors than mice given injections of the cancer cells along with control PSCs. Tumors that formed when KPC cells were injected along with p50<sup>-/-</sup> PSCs had increased infiltration by activated cytotoxic T cells along with decreased levels of CXCL12, compared with tumors grown from KPC cells injected along with control PSCs. KPC cells, when coinjected with control or p50<sup>-/-</sup> PSCs, developed the same-size tumors when CD8<sup>+</sup> T cells were depleted from C57BL/6 mice or in Rag1<sup>-/-</sup> mice. The CXCL12 inhibitor slowed tumor growth and increased tumor infiltration by cytotoxic T cells. In vitro expression of p50 by PSCs reduced T-cell migration toward and killing of cancer cells. When cultured with cancer cells, control PSCs expressed 10-fold higher levels of CXCL12 than p50<sup>-/-</sup> PSCs. The CXCL12 inhibitor increased migration of T cells toward KPC cells in culture.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In studies of mice and cell lines, we found that NFκB activity in PSCs promotes tumor growth by increasing expression of CXCL12, which prevents cytotoxic T cells from infiltrating the tumor and killing cancer cells. Strategies to block CXCL12 in pancreatic tumor cells might increase antitumor immunity.</AbstractText>
          <CopyrightInformation>Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Garg</LastName>
            <ForeName>Bharti</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giri</LastName>
            <ForeName>Bhuwan</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Modi</LastName>
            <ForeName>Shrey</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sethi</LastName>
            <ForeName>Vrishketan</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castro</LastName>
            <ForeName>Iris</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Umland</LastName>
            <ForeName>Oliver</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Diabetes Research Institute, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ban</LastName>
            <ForeName>Yuguang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health Sciences, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lavania</LastName>
            <ForeName>Shweta</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dawra</LastName>
            <ForeName>Rajinder</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Banerjee</LastName>
            <ForeName>Sulagna</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vickers</LastName>
            <ForeName>Selwyn</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Alabama, Birmingham, Alabama.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Merchant</LastName>
            <ForeName>Nipun B</ForeName>
            <Initials>NB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Steven Xi</ForeName>
            <Initials>SX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health Sciences, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gilboa</LastName>
            <ForeName>Eli</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramakrishnan</LastName>
            <ForeName>Sundaram</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saluja</LastName>
            <ForeName>Ashok</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida. Electronic address: asaluja@miami.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dudeja</LastName>
            <ForeName>Vikas</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida. Electronic address: vikas.dudeja@med.miami.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA170946</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA124723</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK117576</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK058694</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK111834</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515256">Cxcl12 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058954" MajorTopicYN="N">Pancreatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CXCR4</Keyword>
        <Keyword MajorTopicYN="Y">Chemokine</Keyword>
        <Keyword MajorTopicYN="Y">Cytokine</Keyword>
        <Keyword MajorTopicYN="Y">Immune Suppression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29909021</ArticleId>
        <ArticleId IdType="mid">NIHMS975559</ArticleId>
        <ArticleId IdType="pmc">PMC6679683</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2018.05.051</ArticleId>
        <ArticleId IdType="pii">S0016-5085(18)34656-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res
1970;13:1–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4921480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan HS. Role of immunologic disturbance in human oncogenesis: some facts and fancies. Br J Cancer
1971;25:620–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2008860</ArticleId>
            <ArticleId IdType="pubmed">4401360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell
2011;144:646–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinay DS, Ryan EP, Pawelec G, et al.
Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol
2015;35
Suppl:S185–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25818339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest
2007;117:1137–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1857231</ArticleId>
            <ArticleId IdType="pubmed">17476343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology
2007;121:1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2265921</ArticleId>
            <ArticleId IdType="pubmed">17386080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol
2006;90:51–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16730261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS. Current perspectives on immunotherapy. Semin Oncol
2014;41
Suppl 5:S14–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25438996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandrescu DT, Ichim TE, Riordan NH, et al.
Immunotherapy for melanoma: current status and perspectives. J Immunother
2010;33:570–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3517185</ArticleId>
            <ArticleId IdType="pubmed">20551839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wormann SM, Diakopoulos KN, Lesina M, et al.
The immune network in pancreatic cancer development and progression. Oncogene
2014;33:2956–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23851493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pure E, Lo A. Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Cancer Immunol Res
2016;4:269–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5452418</ArticleId>
            <ArticleId IdType="pubmed">27036971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delitto D, Delitto AE, DiVita BB, et al.
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Cancer Res
2017;77:672–683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5290036</ArticleId>
            <ArticleId IdType="pubmed">27864347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feig C, Jones JO, Kraman M, et al.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A
2013;110:20212–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3864274</ArticleId>
            <ArticleId IdType="pubmed">24277834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hingorani SR, Wang L, Multani AS, et al.
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell
2005;7:469–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sha WC, Liou HC, Tuomanen EI, et al.
Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell
1995;80:321–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7834752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte MV, Haber PS, Applegate TL, et al.
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut
1998;43:128–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1727174</ArticleId>
            <ArticleId IdType="pubmed">9771417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corbett TH, Roberts BJ, Leopold WR, et al.
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res
1984;44:717–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6692374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mombaerts P, Iacomini J, Johnson RS, et al.
RAG-1-deficient mice have no mature B and T lymphocytes. Cell
1992;68:869–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1547488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol
2010;11:197–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20139988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandrov LB, Nik-Zainal S, Wedge DC, et al.
Signatures of mutational processes in human cancer. Nature
2013;500:415–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3776390</ArticleId>
            <ArticleId IdType="pubmed">23945592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maitra A, Hruban RH. Pancreatic Cancer. Annu Rev Pathol
2008;3:157–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666336</ArticleId>
            <ArticleId IdType="pubmed">18039136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moffitt RA, Marayati R, Flate EL, et al.
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet
2015;47:1168–1178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4912058</ArticleId>
            <ArticleId IdType="pubmed">26343385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KE, Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell
2010;18:448–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3397918</ArticleId>
            <ArticleId IdType="pubmed">21075310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling J, Kang Y, Zhao R, et al.
KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell
2012;21:105–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3360958</ArticleId>
            <ArticleId IdType="pubmed">22264792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nomura A, McGinn O, Dudeja V, et al.
Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Mol Cancer
2015;14:200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4657383</ArticleId>
            <ArticleId IdType="pubmed">26597727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. Clinical Cancer Research
2010;16:2927–2931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20484021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colamussi ML, Secchiero P, Gonelli A, et al.
Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway. J Leukoc Biol
2001;69:263–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11272277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Righi E, Kashiwagi S, Yuan J, et al.
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res
2011;71:5522–5534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3959864</ArticleId>
            <ArticleId IdType="pubmed">21742774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vianello F, Papeta N, Chen T, et al.
Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol
2006;176:2902–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16493048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradford JW, Baldwin AS. IKK/nuclear factor-kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment. Adv Cancer Res
2014;121:125–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24889530</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
